Navigation Links
Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Date:1/8/2008

tment period. The primary efficacy endpoint of the trial will be the increase from baseline in spontaneous bowel movements per week (SBMs per week). Additional endpoints include monitoring of other symptoms of OBD, which will include the Patient Assessment of Constipation Symptoms (PAC-SYM) outcomes tool, and other quality of life measures. Maintenance of opioid analgesic effect will be assessed by measuring changes from baseline in mean daily opioid requirements and daily pain scores. Safety and tolerability will be assessed and pharmacokinetics of the drug will be evaluated. The trial will be conducted in approximately 50 centers in North America and Europe.

About NKTR-118

NKTR-118 is an oral drug that combines Nektar's advanced small molecule PEGylation technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. In preclinical studies, Nektar's PEGylation technology has been shown to reduce penetration of drugs across the blood-brain barrier, an important potential advance for NKTR-118 and possibly many other small molecule therapies.

The peripheral opioid antagonist NKTR-118 targets opioid receptors within the enteric nervous system, which mediate OBD, a symptom complex resulting from opioid use that encompasses constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome, and is generally its most prominent component. Currently, there are no specific drugs approved or specifically indicated to treat OBD or OIC. NKTR-118 has been studied in two Phase 1 trials evaluating the safety, tolerability and pharmacokinetics of single and repeated dose administration of the drug.

In a proof-of-principle Phase 1 trial, single oral doses of NKTR-118 antagonized morphine-induced delay in gastrointestinal transit time demonstrating the potential of the drug to relieve constipation caused by opioid treatment. This effect was seen to increase in a dose-dependent fas
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
7. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
8. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
9. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
10. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
11. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular disease and ... of the Company,s accomplishments in 2014 and its outlook for ... Dear Fellow Shareholders, We would like to ...
(Date:1/22/2015)... (NASDAQ: TECH ) announced today that it ... Simple Plex platform through its Proteins Platform division under ... the previously acquired CyPlex instrument platform from CyVek. ... technology which integrates an innovatively designed microfluidic cartridge with ...
(Date:1/22/2015)... 22, 2015 Increasing sophistication among enterprise buyers of ... purchasing in 2015, says Moravia CMO, ... study by market research firm Common Sense Advisory, 15 ... their translation and localization needs. "From a language industry ...
Breaking Medicine Technology:Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... Comprehensive Care Corporation (OTC BB: CHCR), a leading ... provider for managed care companies throughout the U.S., today ... Rx Inc., has been selected as the new President ... the healthcare industry, is a graduate of the United ...
... -- Dehaier Medical Systems Ltd. (Nasdaq: ... leader in the development, assembly, marketing and sale of ... announced that it will release financial results for the ... on Monday, November 14, 2011 before the start of ...
Cached Medicine Technology:Comprehensive Care Corporation Names Robert R. Kulbick New President 2Comprehensive Care Corporation Names Robert R. Kulbick New President 3Dehaier Medical to Report Third Quarter 2011 Financial Results on November 14 2
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and easy ... treat specific body parts and muscle groups. , IsoComforter, ... use patented cold therapy machine with the innovative IsoTube design ... injuries. IsoComforter has become the industry leader in cold ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Payday lending ... vulnerable communities and cause financial distress to the states ... analysts at Howard University’s Center on Race and Wealth. ... in economic activity, payday loans at the same time ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... (Sept. 20, 2007) A Jekyll-Hyde mechanism that both ... the basis for new cancer-fighting drugs. , Scientists in ... that a certain transcription factora protein that binds to ... genes on and offknown to aid in handling stresses ...
... scientist at Leeds whose research is challenging conventional thinking ... has secured funding to further investigate her findings. , ... Sciences has been awarded 80,000 from Heart Research UK ... affecting the heart muscle cell. , For ...
... the agency is doing , , THURSDAY, Sept. 20 ... prescription medicines for health, many are confused and distrustful ... new survey finds. , In fact, many of those ... and Drug Administration approves drugs, and almost half judged ...
... Developments in Solid Organ Transplantation, DALLAS, ... Review",is the focus of a one-day meeting ... Grapevine, Texas. Co-sponsored by the American Society ... Professionals,(NATCO), the conference agenda contains information about ...
... Increase ... SAN ANTONIO, Sept. 20 AT&T Inc. (NYSE: ... portfolio of radio frequency,identification (RFID) tracking offers for health ... operations of hospitals and other,health care facilities. AT&T ...
... MDA stunning discovery by German scientists may make blood ... as washing your hair. In the October print issue ... that the estimated 100,000 hair follicles on each persons ... EPO, the hormone primarily responsible for the creation of ...
Cached Medicine News:Health News:Heat shock proteins are co-opted for cancer 2Health News:Research to shed new light on how statins benefit heart patients 2Health News:Americans Confused About FDA and Drug Safety 2Health News:Americans Confused About FDA and Drug Safety 3Health News:Americans Confused About FDA and Drug Safety 4Health News:Dallas-Area Transplant Meeting Puts Spotlight on Key Issues 2Health News:AT&T Offers 'Network Industry-First' RFID Solution for Health Care Organizations 2Health News:AT&T Offers 'Network Industry-First' RFID Solution for Health Care Organizations 3Health News: New discovery leaves blood-doping athletes scratching their heads 2
... modular cleanroom for biological safety labs ... cleanliness (to Class 10/ISO 3) and ... create ultra-smooth surfaces that are easy ... radius corners simplify cleaning. Unique double-wall ...
Inquire...
Inquire...
Inquire...
Medicine Products: